[go: up one dir, main page]

MX2013011572A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2013011572A
MX2013011572A MX2013011572A MX2013011572A MX2013011572A MX 2013011572 A MX2013011572 A MX 2013011572A MX 2013011572 A MX2013011572 A MX 2013011572A MX 2013011572 A MX2013011572 A MX 2013011572A MX 2013011572 A MX2013011572 A MX 2013011572A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
relates
oral pharmaceutical
particles
coated
Prior art date
Application number
MX2013011572A
Other languages
English (en)
Other versions
MX352934B (es
Inventor
Ljiljana Sovic Brkicic
Zdravko Dokuzovic
Original Assignee
Ljiljana Sovic Brkicic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ljiljana Sovic Brkicic filed Critical Ljiljana Sovic Brkicic
Publication of MX2013011572A publication Critical patent/MX2013011572A/es
Publication of MX352934B publication Critical patent/MX352934B/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
    • B05D1/22—Processes for applying liquids or other fluent materials performed by dipping using fluidised-bed technique
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/02—Processes for applying liquids or other fluent materials performed by spraying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una composición farmacéutica oral que comprende partículas recubiertas de un complejo de al menos un agente activo con una resina de intercambio iónico, en donde tales partículas se recubren con una capa de cubierta bioadhesiva que comprende al menos un material bioadhesivo. La invención también se refiere a un proceso para preparar composición farmacéutica oral.
MX2013011572A 2011-04-06 2012-04-05 Composicion farmaceutica. MX352934B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11161398A EP2508174A1 (en) 2011-04-06 2011-04-06 Pharmaceutical composition
PCT/EP2012/056366 WO2012136816A2 (en) 2011-04-06 2012-04-05 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2013011572A true MX2013011572A (es) 2014-05-21
MX352934B MX352934B (es) 2017-12-14

Family

ID=44454073

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011572A MX352934B (es) 2011-04-06 2012-04-05 Composicion farmaceutica.

Country Status (21)

Country Link
US (1) US11103891B2 (es)
EP (3) EP2508174A1 (es)
JP (2) JP6144252B2 (es)
KR (1) KR102078885B1 (es)
CN (1) CN103517708B (es)
AP (1) AP3864A (es)
AU (2) AU2012238629A1 (es)
BR (1) BR112013025519B1 (es)
CA (1) CA2832130C (es)
DK (1) DK2694038T3 (es)
EA (1) EA030074B1 (es)
ES (1) ES2743130T3 (es)
HR (1) HRP20191555T1 (es)
HU (1) HUE045928T2 (es)
LT (1) LT2694038T (es)
MX (1) MX352934B (es)
PL (1) PL2694038T3 (es)
PT (1) PT2694038T (es)
RS (1) RS59061B1 (es)
SI (1) SI2694038T1 (es)
WO (1) WO2012136816A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
ES2946549T3 (es) * 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
WO2013123426A1 (en) * 2012-02-18 2013-08-22 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
EP2725072B1 (en) * 2012-10-25 2015-07-22 Rohm and Haas Company Aldehyde abatement with porous amine functional resins
EP2764862A1 (en) * 2013-02-06 2014-08-13 Galenicum Health S.L. Immediate release tablets of rasagiline hemitartrate
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014180912A1 (en) * 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release formulations of lacosamide
CN104146978B (zh) * 2013-05-13 2016-12-28 沈阳药科大学 一种双硫仑肠溶片剂及其制备方法
KR101831535B1 (ko) 2013-07-25 2018-02-22 바스프 에스이 무정형 형태의 다사티닙 염
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
FR3017533B1 (fr) * 2014-02-19 2016-03-11 Cousin Biotech Dispositif implantable, notamment pour la refection de paroi abdominale
JP6577024B2 (ja) * 2014-05-08 2019-09-18 シーティーシー バイオ インコーポレイテッド 味が遮蔽されたクロミプラミン含有経口投与用薬学製剤
WO2015170939A1 (ko) * 2014-05-08 2015-11-12 주식회사 씨티씨바이오 클로미프라민 함유 맛 차폐된 구강 투여용 약학 제제
US20150110871A1 (en) * 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
EP3164155B1 (en) * 2014-06-13 2022-02-09 United Therapeutics Corporation Treprostinil formulations
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
US20150133464A1 (en) * 2015-02-01 2015-05-14 David Wong Injectable particle
PL3261645T3 (pl) 2015-02-27 2021-12-06 Dechra Limited Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
CN105223326B (zh) * 2015-09-23 2017-01-18 天津中医药大学 一种中药口服速释制剂中活性成分的体外分类方法
CN105310980A (zh) * 2015-10-09 2016-02-10 北京万全德众医药生物技术有限公司 帕利哌酮缓释混悬口服液及其制备方法
CN105902500B (zh) * 2016-04-27 2019-11-29 上海理工大学 一种美沙拉嗪肠溶定位控释制剂及其制备方法
KR102544141B1 (ko) * 2016-09-29 2023-06-16 에스케이케미칼 주식회사 라코사미드 서방성 제제
GR1009209B (el) 2016-11-17 2018-02-05 Φαρματεν Αβεε Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
CN108186563A (zh) * 2017-12-06 2018-06-22 江苏大学 苯妥英钠缓释混悬剂及其制备方法
KR20200117999A (ko) * 2017-12-22 2020-10-14 디디피 스페셜티 일렉트로닉 머티리얼즈 유에스 8 엘엘씨 수지 입자를 함유하는 약학적 조성물
CN108057134B (zh) * 2017-12-26 2020-12-01 湖北回盛生物科技有限公司 一种奶牛助产润滑剂及其制备方法
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN108553437A (zh) * 2018-06-08 2018-09-21 姚静 一种通过离子交换技术制得的巯嘌呤咀嚼片及其制备方法
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
CN109966277B (zh) * 2019-05-23 2021-04-30 济宁医学院附属医院 一种治疗难治性癫痫的药物组合物及其应用
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US12201591B2 (en) * 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN110974813B (zh) * 2019-12-06 2021-04-06 四川大学华西医院 奥西那林在抗菌药物中的应用及筛选抗菌药物的方法
CN111494316B (zh) * 2020-04-14 2021-05-18 山东大学 一种载双硫仑的纳米乳原位凝胶剂的制备方法及其应用
CN111840240A (zh) * 2020-05-29 2020-10-30 仁和堂药业有限公司 一种非那雄胺制剂及其应用
CN111840255B (zh) * 2020-07-31 2022-03-01 北京丰帆生物医药科技有限公司 一种维拉帕米温敏缓释制剂及其制备方法和应用
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CN112190573A (zh) * 2020-11-17 2021-01-08 四川大学华西医院 一种治疗肝癌的联合用药物
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
CA3243340A1 (en) * 2022-01-26 2023-08-03 Tulex Pharmaceuticals Inc NEW COMPOSITIONS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO98434A (es) 1959-04-30
US3117027A (en) 1960-01-08 1964-01-07 Wisconsin Alumni Res Found Apparatus for coating particles in a fluidized bed
US3253944A (en) 1964-01-13 1966-05-31 Wisconsin Alumni Res Found Particle coating process
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4847077A (en) 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
US4983400A (en) 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4859461A (en) 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
US4859462A (en) * 1986-07-30 1989-08-22 Fisons Corporation Polymer-treated ion exchange resins
JPS63101332A (ja) * 1986-10-17 1988-05-06 Sato Seiyaku Kk 経口投与用徐放性製剤
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
ES2052681T5 (es) * 1987-12-31 1997-12-01 Asta Medica Ag Combinacion sinergica de inhibidores de descarboxilasa y granulos de l-dopa.
US4959219A (en) 1988-08-15 1990-09-25 Fisons Corporation Coating barriers comprising ethyl cellulose
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
KR0178099B1 (ko) * 1996-08-22 1999-03-20 정도언 방출제어형 이부프로펜 과립제 및 그의 제조방법
WO1998027961A2 (en) 1996-12-20 1998-07-02 Warner Lambert Company Antitussive drugs delivered by partially coated ion exchange resins
IT1295271B1 (it) 1997-10-03 1999-05-04 Chiesi Farma Spa Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US20030224045A1 (en) 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
DE60322103D1 (de) 2002-12-18 2008-08-21 Ferrer Int Pharmazeutische zusammensetzungen mit sertaconazol für vaginale verwendung
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
EP1615665A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
US20050181050A1 (en) 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
RU2484815C2 (ru) 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
WO2008064192A2 (en) * 2006-11-21 2008-05-29 Mcneil-Ppc, Inc. Modified release analgesic suspensions
CA2689101C (en) * 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems

Also Published As

Publication number Publication date
BR112013025519B1 (pt) 2022-02-01
BR112013025519A2 (pt) 2017-12-12
EP2694038B1 (en) 2019-05-29
LT2694038T (lt) 2019-08-26
HUE045928T2 (hu) 2020-01-28
AU2012238629A1 (en) 2013-11-21
EP2508174A1 (en) 2012-10-10
MX352934B (es) 2017-12-14
CA2832130A1 (en) 2012-10-11
HRP20191555T1 (hr) 2019-11-29
PL2694038T3 (pl) 2019-10-31
SI2694038T1 (sl) 2019-10-30
JP6144252B2 (ja) 2017-06-07
EP2694038A2 (en) 2014-02-12
CA2832130C (en) 2019-04-23
JP2014510128A (ja) 2014-04-24
US11103891B2 (en) 2021-08-31
WO2012136816A2 (en) 2012-10-11
CN103517708B (zh) 2016-02-17
RS59061B1 (sr) 2019-08-30
KR20140029435A (ko) 2014-03-10
ES2743130T3 (es) 2020-02-18
JP2017125028A (ja) 2017-07-20
KR102078885B1 (ko) 2020-02-18
AP2013007227A0 (en) 2013-11-30
EP3607938A2 (en) 2020-02-12
WO2012136816A3 (en) 2013-01-31
AU2017203939B2 (en) 2019-05-30
AP3864A (en) 2016-10-31
EP3607938A3 (en) 2020-04-22
EA030074B1 (ru) 2018-06-29
CN103517708A (zh) 2014-01-15
AU2017203939A1 (en) 2017-07-06
DK2694038T3 (da) 2019-08-19
US20140154328A1 (en) 2014-06-05
EA201391483A1 (ru) 2014-05-30
PT2694038T (pt) 2019-08-01

Similar Documents

Publication Publication Date Title
MX352934B (es) Composicion farmaceutica.
EP2781567B8 (en) Antifouling coating composition, antifouling coating film, anti-foul base material, and process for manufacturing anti-foul base material
SG11201408656WA (en) Powder coating composition, process for producing cured film and coated article
EP2669289A4 (en) QUINOLINE-LIKE COMPOUND CONTAINING A PHOSPHORUS-SUBSTITUTED GROUP, PREPARATION METHOD, MEDICAL COMPOSITION CONTAINING THE COMPOUND, AND APPLICATION
EP2773708B8 (en) A coating composition, a method for coating a substrate, a coated substrate, a packaging material and a liquid package
MX2014002409A (es) Cermet en polvo.
IL239325A0 (en) An oral dosage form that includes crush-resistant coated particles for immediate release of at least one active compound
PL2563967T3 (pl) Sposób wytwarzania materiałów kompozytowych na bazie żelu
EP2679625A4 (en) AQUEOUS LIQUID COMPOSITION, AQUEOUS COATING, FUNCTIONAL COATING FILM, AND COMPOSITE MATERIAL
UY35047A (es) Procedimiento de preparación de un fertilizante de liberación lenta
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
IN2015DN01286A (es)
PL2770827T3 (pl) Kompozycja, sposób otrzymywania kompozycji i zawierająca ją formulacja fitosanitarna
AU2012319844A8 (en) Composite structure, packaging material and formed product using same, production methods thereof, and coating liquid
AU2011373908A8 (en) Whey protein coated films
AU2012283745A1 (en) Process for the manufacture of multilayer articles
EP3239158A4 (en) Organosilicon compound containing isocyanate group, process for producing same, adhesive, pressure-sensitive adhesive, and coating material
MX2013008197A (es) Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
AP2012006645A0 (en) Pharmaceutical compositions comprising paracetamoland process for preparing the same
IL222377A0 (en) Coating source and process for the production thereof
PH12014502325A1 (en) Sustained release tablet containing levodropropizine and method for preparing same
ZA201308542B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
CA2818993A1 (en) Modulators of s1p receptors
ZA201600185B (en) Coating material composition, and coated films obtained by the coating thereof
AP2012006149A0 (en) New dihydro-oxazolobenzodiazepinone compounds, a process for their preparation and pharmaceutical compositions containing them.

Legal Events

Date Code Title Description
FG Grant or registration